Wockhardt's Strategic Exit: Impact on Financial Health
Wockhardt Ltd reported a substantial loss of Rs 108 crore in the June quarter due to impairments after exiting the US generics business. Despite a slight dip in revenue, the company's decision to liquidate its US subsidiaries has led to a significant financial impact.
- Country:
- India
Pharmaceutical giant Wockhardt Ltd has announced a significant widening of its losses, reporting a Rs 108 crore loss after tax for the June quarter. The decline is primarily attributed to impairments caused by the company's strategic withdrawal from the US generics market.
The firm, which faced a marginal drop in revenue to Rs 738 crore this quarter, compared to Rs 739 crore in the same period last year, has been visibly impacted by the liquidation of its American subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC.
Despite the fall in total expenses to Rs 770 crore from Rs 775 crore a year ago, the financial strain from impairing Rs 97 crore in goodwill has highlighted the challenges faced by Wockhardt in navigating its transition away from the US generic pharmaceutical sector.
(With inputs from agencies.)
Google News